The global Blood Cancer Drugs market was valued at US$ 62740 million in 2023 and is anticipated to reach US$ 91940 million by 2030, witnessing a CAGR of 5.5% during the forecast period 2024-2030.

Blood Cancer Drugs Market

Blood cancers, or hematologic cancers, affect the production and function of blood cells. Most of these cancers start in the bone marrow where blood is produced.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Blood Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Blood Cancer Drugs.

Report Scope

The Blood Cancer Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Blood Cancer Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Blood Cancer Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Blood Cancer Drugs Market Report

Report Metric	Details
Report Name	Blood Cancer Drugs Market
Accounted market size in 2023	US$ 62740 million
Forecasted market size in 2030	US$ 91940 million
CAGR	5.5%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Blood Chemotherapy Drugs Blood Targeted Therapy Drugs
Segment by Application	Leukemia lymphoma Multiple Myeloma
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Amgen,, AstraZeneca PLC,, Astellas Pharma,, Bayer AG,, Bristol-Myers Squibb Company,, Celgene Corporation,, Eli Lilly,, F.Hoffmann-La Roche,, Johnson & Johnson,, Novartis, Pfizer,, Takeda Pharmaceutical Company Ltd,, AbbVie
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Blood Cancer Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Blood Cancer Drugs Market growing?

Ans: The Blood Cancer Drugs Market witnessing a CAGR of 5.5% during the forecast period 2024-2030.

What is the Blood Cancer Drugs Market size in 2030?

Ans: The Blood Cancer Drugs Market size in 2030 will be US$ 91940 million.

Who are the main players in the Blood Cancer Drugs Market report?

Ans: The main players in the Blood Cancer Drugs Market are Amgen,, AstraZeneca PLC,, Astellas Pharma,, Bayer AG,, Bristol-Myers Squibb Company,, Celgene Corporation,, Eli Lilly,, F.Hoffmann-La Roche,, Johnson & Johnson,, Novartis, Pfizer,, Takeda Pharmaceutical Company Ltd,, AbbVie

What are the Application segmentation covered in the Blood Cancer Drugs Market report?

Ans: The Applications covered in the Blood Cancer Drugs Market report are Leukemia, lymphoma, Multiple Myeloma

What are the Type segmentation covered in the Blood Cancer Drugs Market report?

Ans: The Types covered in the Blood Cancer Drugs Market report are Blood Chemotherapy Drugs, Blood Targeted Therapy Drugs

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Blood Cancer Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Blood Chemotherapy Drugs

1.2.3 Blood Targeted Therapy Drugs

1.3 Market by Application

1.3.1 Global Blood Cancer Drugs Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Leukemia

1.3.3 lymphoma

1.3.4 Multiple Myeloma

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Blood Cancer Drugs Market Perspective (2019-2030)

2.2 Blood Cancer Drugs Growth Trends by Region

2.2.1 Global Blood Cancer Drugs Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Blood Cancer Drugs Historic Market Size by Region (2019-2024)

2.2.3 Blood Cancer Drugs Forecasted Market Size by Region (2025-2030)

2.3 Blood Cancer Drugs Market Dynamics

2.3.1 Blood Cancer Drugs Industry Trends

2.3.2 Blood Cancer Drugs Market Drivers

2.3.3 Blood Cancer Drugs Market Challenges

2.3.4 Blood Cancer Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Blood Cancer Drugs Players by Revenue

3.1.1 Global Top Blood Cancer Drugs Players by Revenue (2019-2024)

3.1.2 Global Blood Cancer Drugs Revenue Market Share by Players (2019-2024)

3.2 Global Blood Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Blood Cancer Drugs Revenue

3.4 Global Blood Cancer Drugs Market Concentration Ratio

3.4.1 Global Blood Cancer Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Blood Cancer Drugs Revenue in 2023

3.5 Blood Cancer Drugs Key Players Head office and Area Served

3.6 Key Players Blood Cancer Drugs Product Solution and Service

3.7 Date of Enter into Blood Cancer Drugs Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Blood Cancer Drugs Breakdown Data by Type

4.1 Global Blood Cancer Drugs Historic Market Size by Type (2019-2024)

4.2 Global Blood Cancer Drugs Forecasted Market Size by Type (2025-2030)

5 Blood Cancer Drugs Breakdown Data by Application

5.1 Global Blood Cancer Drugs Historic Market Size by Application (2019-2024)

5.2 Global Blood Cancer Drugs Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Blood Cancer Drugs Market Size (2019-2030)

6.2 North America Blood Cancer Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Blood Cancer Drugs Market Size by Country (2019-2024)

6.4 North America Blood Cancer Drugs Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Blood Cancer Drugs Market Size (2019-2030)

7.2 Europe Blood Cancer Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Blood Cancer Drugs Market Size by Country (2019-2024)

7.4 Europe Blood Cancer Drugs Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Blood Cancer Drugs Market Size (2019-2030)

8.2 Asia-Pacific Blood Cancer Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Blood Cancer Drugs Market Size by Region (2019-2024)

8.4 Asia-Pacific Blood Cancer Drugs Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Blood Cancer Drugs Market Size (2019-2030)

9.2 Latin America Blood Cancer Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Blood Cancer Drugs Market Size by Country (2019-2024)

9.4 Latin America Blood Cancer Drugs Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Blood Cancer Drugs Market Size (2019-2030)

10.2 Middle East & Africa Blood Cancer Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Blood Cancer Drugs Market Size by Country (2019-2024)

10.4 Middle East & Africa Blood Cancer Drugs Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Amgen,

11.1.1 Amgen, Company Detail

11.1.2 Amgen, Business Overview

11.1.3 Amgen, Blood Cancer Drugs Introduction

11.1.4 Amgen, Revenue in Blood Cancer Drugs Business (2019-2024)

11.1.5 Amgen, Recent Development

11.2 AstraZeneca PLC,

11.2.1 AstraZeneca PLC, Company Detail

11.2.2 AstraZeneca PLC, Business Overview

11.2.3 AstraZeneca PLC, Blood Cancer Drugs Introduction

11.2.4 AstraZeneca PLC, Revenue in Blood Cancer Drugs Business (2019-2024)

11.2.5 AstraZeneca PLC, Recent Development

11.3 Astellas Pharma,

11.3.1 Astellas Pharma, Company Detail

11.3.2 Astellas Pharma, Business Overview

11.3.3 Astellas Pharma, Blood Cancer Drugs Introduction

11.3.4 Astellas Pharma, Revenue in Blood Cancer Drugs Business (2019-2024)

11.3.5 Astellas Pharma, Recent Development

11.4 Bayer AG,

11.4.1 Bayer AG, Company Detail

11.4.2 Bayer AG, Business Overview

11.4.3 Bayer AG, Blood Cancer Drugs Introduction

11.4.4 Bayer AG, Revenue in Blood Cancer Drugs Business (2019-2024)

11.4.5 Bayer AG, Recent Development

11.5 Bristol-Myers Squibb Company,

11.5.1 Bristol-Myers Squibb Company, Company Detail

11.5.2 Bristol-Myers Squibb Company, Business Overview

11.5.3 Bristol-Myers Squibb Company, Blood Cancer Drugs Introduction

11.5.4 Bristol-Myers Squibb Company, Revenue in Blood Cancer Drugs Business (2019-2024)

11.5.5 Bristol-Myers Squibb Company, Recent Development

11.6 Celgene Corporation,

11.6.1 Celgene Corporation, Company Detail

11.6.2 Celgene Corporation, Business Overview

11.6.3 Celgene Corporation, Blood Cancer Drugs Introduction

11.6.4 Celgene Corporation, Revenue in Blood Cancer Drugs Business (2019-2024)

11.6.5 Celgene Corporation, Recent Development

11.7 Eli Lilly,

11.7.1 Eli Lilly, Company Detail

11.7.2 Eli Lilly, Business Overview

11.7.3 Eli Lilly, Blood Cancer Drugs Introduction

11.7.4 Eli Lilly, Revenue in Blood Cancer Drugs Business (2019-2024)

11.7.5 Eli Lilly, Recent Development

11.8 F.Hoffmann-La Roche,

11.8.1 F.Hoffmann-La Roche, Company Detail

11.8.2 F.Hoffmann-La Roche, Business Overview

11.8.3 F.Hoffmann-La Roche, Blood Cancer Drugs Introduction

11.8.4 F.Hoffmann-La Roche, Revenue in Blood Cancer Drugs Business (2019-2024)

11.8.5 F.Hoffmann-La Roche, Recent Development

11.9 Johnson & Johnson,

11.9.1 Johnson & Johnson, Company Detail

11.9.2 Johnson & Johnson, Business Overview

11.9.3 Johnson & Johnson, Blood Cancer Drugs Introduction

11.9.4 Johnson & Johnson, Revenue in Blood Cancer Drugs Business (2019-2024)

11.9.5 Johnson & Johnson, Recent Development

11.10 Novartis

11.10.1 Novartis Company Detail

11.10.2 Novartis Business Overview

11.10.3 Novartis Blood Cancer Drugs Introduction

11.10.4 Novartis Revenue in Blood Cancer Drugs Business (2019-2024)

11.10.5 Novartis Recent Development

11.11 Pfizer,

11.11.1 Pfizer, Company Detail

11.11.2 Pfizer, Business Overview

11.11.3 Pfizer, Blood Cancer Drugs Introduction

11.11.4 Pfizer, Revenue in Blood Cancer Drugs Business (2019-2024)

11.11.5 Pfizer, Recent Development

11.12 Takeda Pharmaceutical Company Ltd,

11.12.1 Takeda Pharmaceutical Company Ltd, Company Detail

11.12.2 Takeda Pharmaceutical Company Ltd, Business Overview

11.12.3 Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Introduction

11.12.4 Takeda Pharmaceutical Company Ltd, Revenue in Blood Cancer Drugs Business (2019-2024)

11.12.5 Takeda Pharmaceutical Company Ltd, Recent Development

11.13 AbbVie

11.13.1 AbbVie Company Detail

11.13.2 AbbVie Business Overview

11.13.3 AbbVie Blood Cancer Drugs Introduction

11.13.4 AbbVie Revenue in Blood Cancer Drugs Business (2019-2024)

11.13.5 AbbVie Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Bristol Myers Squibb Company

Takeda Pharmaceutical Company Ltd

AbbVie

List of Tables

Table 1. Global Blood Cancer Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Blood Chemotherapy Drugs

Table 3. Key Players of Blood Targeted Therapy Drugs

Table 4. Global Blood Cancer Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 5. Global Blood Cancer Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Blood Cancer Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 7. Global Blood Cancer Drugs Market Share by Region (2019-2024)

Table 8. Global Blood Cancer Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 9. Global Blood Cancer Drugs Market Share by Region (2025-2030)

Table 10. Blood Cancer Drugs Market Trends

Table 11. Blood Cancer Drugs Market Drivers

Table 12. Blood Cancer Drugs Market Challenges

Table 13. Blood Cancer Drugs Market Restraints

Table 14. Global Blood Cancer Drugs Revenue by Players (2019-2024) & (US$ Million)

Table 15. Global Blood Cancer Drugs Market Share by Players (2019-2024)

Table 16. Global Top Blood Cancer Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Blood Cancer Drugs as of 2023)

Table 17. Ranking of Global Top Blood Cancer Drugs Companies by Revenue (US$ Million) in 2023

Table 18. Global 5 Largest Players Market Share by Blood Cancer Drugs Revenue (CR5 and HHI) & (2019-2024)

Table 19. Key Players Headquarters and Area Served

Table 20. Key Players Blood Cancer Drugs Product Solution and Service

Table 21. Date of Enter into Blood Cancer Drugs Market

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Blood Cancer Drugs Market Size by Type (2019-2024) & (US$ Million)

Table 24. Global Blood Cancer Drugs Revenue Market Share by Type (2019-2024)

Table 25. Global Blood Cancer Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 26. Global Blood Cancer Drugs Revenue Market Share by Type (2025-2030)

Table 27. Global Blood Cancer Drugs Market Size by Application (2019-2024) & (US$ Million)

Table 28. Global Blood Cancer Drugs Revenue Market Share by Application (2019-2024)

Table 29. Global Blood Cancer Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 30. Global Blood Cancer Drugs Revenue Market Share by Application (2025-2030)

Table 31. North America Blood Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 32. North America Blood Cancer Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 33. North America Blood Cancer Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 34. Europe Blood Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. Europe Blood Cancer Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 36. Europe Blood Cancer Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 37. Asia-Pacific Blood Cancer Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 38. Asia-Pacific Blood Cancer Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 39. Asia-Pacific Blood Cancer Drugs Market Size by Region (2025-2030) & (US$ Million)

Table 40. Latin America Blood Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 41. Latin America Blood Cancer Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 42. Latin America Blood Cancer Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 43. Middle East & Africa Blood Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Middle East & Africa Blood Cancer Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 45. Middle East & Africa Blood Cancer Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 46. Amgen, Company Detail

Table 47. Amgen, Business Overview

Table 48. Amgen, Blood Cancer Drugs Product

Table 49. Amgen, Revenue in Blood Cancer Drugs Business (2019-2024) & (US$ Million)

Table 50. Amgen, Recent Development

Table 51. AstraZeneca PLC, Company Detail

Table 52. AstraZeneca PLC, Business Overview

Table 53. AstraZeneca PLC, Blood Cancer Drugs Product

Table 54. AstraZeneca PLC, Revenue in Blood Cancer Drugs Business (2019-2024) & (US$ Million)

Table 55. AstraZeneca PLC, Recent Development

Table 56. Astellas Pharma, Company Detail

Table 57. Astellas Pharma, Business Overview

Table 58. Astellas Pharma, Blood Cancer Drugs Product

Table 59. Astellas Pharma, Revenue in Blood Cancer Drugs Business (2019-2024) & (US$ Million)

Table 60. Astellas Pharma, Recent Development

Table 61. Bayer AG, Company Detail

Table 62. Bayer AG, Business Overview

Table 63. Bayer AG, Blood Cancer Drugs Product

Table 64. Bayer AG, Revenue in Blood Cancer Drugs Business (2019-2024) & (US$ Million)

Table 65. Bayer AG, Recent Development

Table 66. Bristol-Myers Squibb Company, Company Detail

Table 67. Bristol-Myers Squibb Company, Business Overview

Table 68. Bristol-Myers Squibb Company, Blood Cancer Drugs Product

Table 69. Bristol-Myers Squibb Company, Revenue in Blood Cancer Drugs Business (2019-2024) & (US$ Million)

Table 70. Bristol-Myers Squibb Company, Recent Development

Table 71. Celgene Corporation, Company Detail

Table 72. Celgene Corporation, Business Overview

Table 73. Celgene Corporation, Blood Cancer Drugs Product

Table 74. Celgene Corporation, Revenue in Blood Cancer Drugs Business (2019-2024) & (US$ Million)

Table 75. Celgene Corporation, Recent Development

Table 76. Eli Lilly, Company Detail

Table 77. Eli Lilly, Business Overview

Table 78. Eli Lilly, Blood Cancer Drugs Product

Table 79. Eli Lilly, Revenue in Blood Cancer Drugs Business (2019-2024) & (US$ Million)

Table 80. Eli Lilly, Recent Development

Table 81. F.Hoffmann-La Roche, Company Detail

Table 82. F.Hoffmann-La Roche, Business Overview

Table 83. F.Hoffmann-La Roche, Blood Cancer Drugs Product

Table 84. F.Hoffmann-La Roche, Revenue in Blood Cancer Drugs Business (2019-2024) & (US$ Million)

Table 85. F.Hoffmann-La Roche, Recent Development

Table 86. Johnson & Johnson, Company Detail

Table 87. Johnson & Johnson, Business Overview

Table 88. Johnson & Johnson, Blood Cancer Drugs Product

Table 89. Johnson & Johnson, Revenue in Blood Cancer Drugs Business (2019-2024) & (US$ Million)

Table 90. Johnson & Johnson, Recent Development

Table 91. Novartis Company Detail

Table 92. Novartis Business Overview

Table 93. Novartis Blood Cancer Drugs Product

Table 94. Novartis Revenue in Blood Cancer Drugs Business (2019-2024) & (US$ Million)

Table 95. Novartis Recent Development

Table 96. Pfizer, Company Detail

Table 97. Pfizer, Business Overview

Table 98. Pfizer, Blood Cancer Drugs Product

Table 99. Pfizer, Revenue in Blood Cancer Drugs Business (2019-2024) & (US$ Million)

Table 100. Pfizer, Recent Development

Table 101. Takeda Pharmaceutical Company Ltd, Company Detail

Table 102. Takeda Pharmaceutical Company Ltd, Business Overview

Table 103. Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Product

Table 104. Takeda Pharmaceutical Company Ltd, Revenue in Blood Cancer Drugs Business (2019-2024) & (US$ Million)

Table 105. Takeda Pharmaceutical Company Ltd, Recent Development

Table 106. AbbVie Company Detail

Table 107. AbbVie Business Overview

Table 108. AbbVie Blood Cancer Drugs Product

Table 109. AbbVie Revenue in Blood Cancer Drugs Business (2019-2024) & (US$ Million)

Table 110. AbbVie Recent Development

Table 111. Research Programs/Design for This Report

Table 112. Key Data Information from Secondary Sources

Table 113. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Blood Cancer Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Blood Cancer Drugs Market Share by Type: 2023 VS 2030

Figure 3. Blood Chemotherapy Drugs Features

Figure 4. Blood Targeted Therapy Drugs Features

Figure 5. Global Blood Cancer Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 6. Global Blood Cancer Drugs Market Share by Application: 2023 VS 2030

Figure 7. Leukemia Case Studies

Figure 8. lymphoma Case Studies

Figure 9. Multiple Myeloma Case Studies

Figure 10. Blood Cancer Drugs Report Years Considered

Figure 11. Global Blood Cancer Drugs Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 12. Global Blood Cancer Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 13. Global Blood Cancer Drugs Market Share by Region: 2023 VS 2030

Figure 14. Global Blood Cancer Drugs Market Share by Players in 2023

Figure 15. Global Top Blood Cancer Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Blood Cancer Drugs as of 2023)

Figure 16. The Top 10 and 5 Players Market Share by Blood Cancer Drugs Revenue in 2023

Figure 17. North America Blood Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 18. North America Blood Cancer Drugs Market Share by Country (2019-2030)

Figure 19. United States Blood Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. Canada Blood Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. Europe Blood Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Europe Blood Cancer Drugs Market Share by Country (2019-2030)

Figure 23. Germany Blood Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. France Blood Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. U.K. Blood Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Italy Blood Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Russia Blood Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Nordic Countries Blood Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Asia-Pacific Blood Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Asia-Pacific Blood Cancer Drugs Market Share by Region (2019-2030)

Figure 31. China Blood Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Japan Blood Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. South Korea Blood Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Southeast Asia Blood Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. India Blood Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Australia Blood Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Latin America Blood Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Latin America Blood Cancer Drugs Market Share by Country (2019-2030)

Figure 39. Mexico Blood Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Brazil Blood Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Middle East & Africa Blood Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Middle East & Africa Blood Cancer Drugs Market Share by Country (2019-2030)

Figure 43. Turkey Blood Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Saudi Arabia Blood Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Amgen, Revenue Growth Rate in Blood Cancer Drugs Business (2019-2024)

Figure 46. AstraZeneca PLC, Revenue Growth Rate in Blood Cancer Drugs Business (2019-2024)

Figure 47. Astellas Pharma, Revenue Growth Rate in Blood Cancer Drugs Business (2019-2024)

Figure 48. Bayer AG, Revenue Growth Rate in Blood Cancer Drugs Business (2019-2024)

Figure 49. Bristol-Myers Squibb Company, Revenue Growth Rate in Blood Cancer Drugs Business (2019-2024)

Figure 50. Celgene Corporation, Revenue Growth Rate in Blood Cancer Drugs Business (2019-2024)

Figure 51. Eli Lilly, Revenue Growth Rate in Blood Cancer Drugs Business (2019-2024)

Figure 52. F.Hoffmann-La Roche, Revenue Growth Rate in Blood Cancer Drugs Business (2019-2024)

Figure 53. Johnson & Johnson, Revenue Growth Rate in Blood Cancer Drugs Business (2019-2024)

Figure 54. Novartis Revenue Growth Rate in Blood Cancer Drugs Business (2019-2024)

Figure 55. Pfizer, Revenue Growth Rate in Blood Cancer Drugs Business (2019-2024)

Figure 56. Takeda Pharmaceutical Company Ltd, Revenue Growth Rate in Blood Cancer Drugs Business (2019-2024)

Figure 57. AbbVie Revenue Growth Rate in Blood Cancer Drugs Business (2019-2024)

Figure 58. Bottom-up and Top-down Approaches for This Report

Figure 59. Data Triangulation

Figure 60. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions